Latest Articles
-
Is COIN Stock A Buy As Stablecoin Bill Clears The Senate?
Coinbase Global (NASDAQ:COIN) stock surged by 16% in Wednesday’s trading and remains up by almost 20% over the past week. The rally comes following the passage of the much-anticipated stablecoin regulation bill through the Senate. Stablecoi...
-
What’s Behind The 2x Rise In Microsoft Stock?
With a 15% year-to-date (YTD) gain, Microsoft stock (NASDAQ:MSFT) has significantly outperformed the broader S&P 500 index, which is up just 2%. This strong performance is largely attributed to increased demand for Azure, fueled by the ongoin...
-
Is Philip Morris Stock A Better Pick Over Alphabet Stock?
Question: Why would anyone pay 37 times earnings for Philip Morris stock when Google stock is available at a more attractive valuation of 19 times earnings? Most wouldn’t—especially when considering three key points: Growth: Google’s revenue i...
-
Buy, Sell, Or Hold SOFI Stock At $15?
SoFi stock (NASDAQ: SOFI) has jumped more than 15% over the past month. This upward move seems to be partially driven by Chime’s successful IPO, which has positively influenced sentiment across the fintech space. After a prolonged lull in public ...
-
Lululemon’s 40% Drop Looks Overdone – Here’s Why
Lululemon stock (NASDAQ: LULU) has shed 30% since reporting Q1 2025 earnings and now trades around $229, down 40% year-to-date, sharply lagging the S&P 500’s 2% gain. Yet the selloff looks more sentiment-driven than fundamentally justified. ...
-
Is Oklo Stock Worth The Risk?
Oklo (NYSE:OKLO), a nuclear energy startup backed by OpenAI’s Sam Altman, has surged more than 6x over the past 12 months. The stock is also up by over 55% over the last month or so. So what’s driving the gains? And is Oklo stock stil...
-
How Will FedEx Stock React To Its Upcoming Earnings?
FedEx (NYSE:FDX) will announce its fiscal Q4 2025 earnings on Tuesday, June 24, 2025. Historically, FedEx’s stock has shown mixed reactions to earnings announcements over the past five years. Post-earnings, the stock has seen positive one-d...
-
Are Stablecoins A Real Threat to Visa and Mastercard Stock?
Visa stock (NYSE: V) and Mastercard stock (NYSE:MA) fell about 5% apiece on Wednesday, June 18th, as investors reacted to growing concerns that stablecoins could threaten traditional payment networks following the U.S. Senate’s passage of landmar...
-
Is This the Market’s Most Mispriced Clean Energy Stock?
First Solar (NASDAQ: FSLR) has posted a 14% year-to-date loss in the last week, well behind the broader market. But behind the drop lies a more nuanced story: shifting energy policy, strong fundamentals, and a valuation that may tempt long-term...
-
What Factors Drove A 2x Rise In Alphabet Stock?
With a 7% decline year-to-date (YTD), Google’s stock (NASDAQ:GOOG) has lagged behind the S&P 500, which has risen by 2%. This underperformance is partly attributed to heightened regulatory scrutiny and rising investor concerns about the poten...
-
After a 27% Surge, Is Tapestry Stock Still Worth Buying?
Note: Tapestry’s FY’24 ended on June 29, 2024 . Luxury fashion house Tapestry (NYSE: TPR) has surged 27% year-to-date, handily beating the S&P 500’s 2% return and outpacing peer Ralph Lauren’s (NYSE: RL) 15% rise. Its mom...
-
Buy, Sell, Or Hold GILD Stock?
Despite a recent setback involving an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to declines in CD4+ T-cell counts, Gilead Sciences (NASDAQ:GILD) has posted a strong year-to-date performance, with its stock rising 18%...
-
Archer Aviation By The Numbers
Archer Aviation (NYSE: ACHR) is making notable strides in the emerging electric vertical take-off and landing (eVTOL) space, as reflected in its stock soaring over 200% in the past year. This surge has been driven by strong demand for its Midnigh...
-
What’s New With BP Stock?
BP plc stock (NYSE: BP) is up around 7% year-to-date, slightly outpacing the S&P 500’s 2% gain. Trading at approximately $32 per share, the British oil major appears cheap on a relative valuation basis – but the underlying narrative is...
-
Eli Lilly Diversifies With Verve Gene Therapy Deal
Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s 30-day volume-weighted average price, causing Verve’s ...
